Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Public ClinicalTrials.gov record NCT04551911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)
Study identification
- NCT ID
- NCT04551911
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Enrollment
- 171 participants
Conditions and interventions
Conditions
Interventions
- Rayaldee Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 1, 2020
- Primary completion
- Oct 7, 2021
- Completion
- Oct 7, 2021
- Last update posted
- May 27, 2024
2020 – 2021
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| OPKO Investigative Site | San Francisco | California | 94127 | — |
| OPKO Investigative Site | Miami | Florida | 33173 | — |
| OPKO Investigative Site | Miami | Florida | 33185 | — |
| OPKO Investigative Site | Evanston | Illinois | 60201 | — |
| OPKO Investigative Site | Laurel | Maryland | 20723 | — |
| OPKO Investigative Site | Farmington Hills | Michigan | 48334 | — |
| OPKO Investigative Site | Jackson | Michigan | 49201 | — |
| OPKO Investigative Site | Sterling Heights | Michigan | 48312 | — |
| OPKO Investigative Site | Brookhaven | Mississippi | 39601 | — |
| OPKO Investigative Site | Omaha | Nebraska | 68131 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04551911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04551911 live on ClinicalTrials.gov.